Moderna (NASDAQ:MRNA) Price Target Raised to $163.00

Moderna (NASDAQ:MRNA) had its price target hoisted by Oppenheimer from $142.00 to $163.00 in a report issued on Friday morning, Benzinga reports. They currently have an outperform rating on the stock.

Several other brokerages have also recently commented on MRNA. Canaccord Genuity Group upped their target price on Moderna from $82.00 to $91.00 and gave the company a hold rating in a report on Friday, February 23rd. Royal Bank of Canada reissued an outperform rating and set a $125.00 target price on shares of Moderna in a research note on Thursday, March 28th. HSBC reissued a reduce rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Needham & Company LLC reiterated a hold rating on shares of Moderna in a report on Thursday. Finally, William Blair restated a market perform rating on shares of Moderna in a report on Monday, April 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Moderna has a consensus rating of Hold and a consensus price target of $129.55.

Moderna Trading Down 2.3 %

NASDAQ MRNA traded down $2.87 on Friday, hitting $122.13. The company’s stock had a trading volume of 3,933,672 shares, compared to its average volume of 4,142,350. The company’s 50-day moving average is $105.05 and its 200 day moving average is $94.48. Moderna has a 1-year low of $62.55 and a 1-year high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The business had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s quarterly revenue was down 91.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.19 earnings per share. As a group, equities analysts predict that Moderna will post -7.47 earnings per share for the current year.

Insiders Place Their Bets

In related news, President Stephen Hoge sold 2,388 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $225,833.16. Following the transaction, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the sale, the director now owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The disclosure for this sale can be found here. Insiders have sold 139,954 shares of company stock valued at $14,822,576 in the last three months. 15.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Moderna

Institutional investors and hedge funds have recently bought and sold shares of the company. International Assets Investment Management LLC increased its holdings in Moderna by 6,528.9% in the 4th quarter. International Assets Investment Management LLC now owns 387,656 shares of the company’s stock worth $38,552,000 after acquiring an additional 381,808 shares during the last quarter. abrdn plc increased its stake in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Van ECK Associates Corp raised its position in shares of Moderna by 19.2% in the fourth quarter. Van ECK Associates Corp now owns 270,774 shares of the company’s stock valued at $26,929,000 after purchasing an additional 43,646 shares during the period. Invesco Ltd. lifted its stake in shares of Moderna by 19.8% during the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after buying an additional 517,683 shares in the last quarter. Finally, Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD boosted its holdings in Moderna by 10.5% in the 3rd quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD now owns 32,188 shares of the company’s stock worth $3,252,000 after buying an additional 3,052 shares during the period. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.